Overview
Survodutide is an experimental peptide developed by Boehringer Ingelheim and Zealand Pharma for weight loss and fatty liver disease. It acts on the GLP-1 and glucagon receptors.
Survodutide is not approved by the Food and Drug Administration for human use, and no prescription version exists. It should only be used within an approved clinical study and never taken without a doctor’s authorization.
What is it being studied for?
Research is focused on weight loss, fatty liver disease with scarring, and type 2 diabetes.
GLP-1 signaling affects appetite and blood sugar. Glucagon signaling affects energy use and liver metabolism.
What has research found?
In a study of people with fatty liver inflammation and scarring, survodutide improved liver inflammation more often than placebo without worsening scarring.
In a separate 46-week obesity study, participants receiving the highest study dose lost about 15 percent of their starting body weight.
Animal studies also found effects on body weight. The most common side effects in human trials were digestive and occurred mainly while study doses were increased.
FDA status and development history
Survodutide is not FDA-approved. Published studies include animal research and human trials for obesity and fatty liver disease.